

ST98017

CLAIMS

1. Monoclonal antibody directed against the G3BP protein and capable of inducing apoptosis in various types of tumour cells.

2. Monoclonal antibody capable of recognizing an epitope between the amino acids situated at positions 1 and 144 of the G3BP protein.

3. Monoclonal antibody according to claim 1 or 2, capable of recognizing an epitope between the amino acids situated at positions 1 to 72 of the G3BP protein, preferably an epitope between the amino acids situated at positions 22 to 55 of the G3BP protein, and preferably still an epitope consisting of the amino acids situated at positions 22 to 34.

4. Antibody according to claims 1 to 3, characterized in that it is the antibody Mab 1F1, secreted by the hybridoma line G3B 1F1 1D1 deposited on 9 June 1998 at the C.N.C.M. under the number I-2038.

5. Use of an antibody according to one of claims 1 to 4 for obtaining a medicine.

6. Use of an antibody according to one of claims 1 to 4 for obtaining a medicine intended for the treatment or prevention of hyperproliferative disorders.

7. Pharmaceutical composition comprising a therapeutically effective quantity of the monoclonal antibodies according to one of claims 1 to 4,

ST98017

optionally mixed with a pharmaceutically acceptable carrier, the said quantity being therapeutically effective for inducing apoptosis in tumour cells.

8. Hybridoma line capable of secreting
5 monoclonal antibodies according to one of claims 1 to 4.

9. Hybridoma line G3B 1F1 1D1 deposited on
9 June 1998 at the C.N.C.M. under the deposit number I-2038.

DEPOSIT

10 10. Method of producing monoclonal antibodies capable of inducing apoptosis in various tumour lines, characterized in that it comprises (1) the fusion of spleen cells from an animal immunized with the aid of the G3BP protein or of a fragment
15 comprising at least a portion of the N-terminal domain (aa 1-144), with myelomatous cells under conditions allowing the formation of hybridomas; (2) the detection and isolation of those of the said hybridomas which secrete monoclonal antibodies capable of inducing
20 apoptosis in various tumour lines.

11. Use of an antibody according to one of claims 1 to 4, as diagnostic reagent.

12. Diagnostic kit characterized in that it comprises an antibody according to one of claims 1 to
25 4.